Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Benefits of exercise during chemotherapy for breast cancer

Helene Rundqvist • 14 Sep 2024
ESMO 2024
Breast Cancer

Helene Rundqvist, PhD, Karolinska Institutet, Solna, Sweden, highlights the importance of exercise for patients undergoing chemotherapy for breast cancer. Findings from multiple studies showing that regular exercise during treatment significantly alleviates side effects, enhances quality of life, reduces fatigue, and helps maintain physical function, including fitness and muscle strength. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Helene Rundqvist

8-year follow-up of the OptiTrain trial: exercise improve survival and recurrence in breast cancer
2:20
8-year follow-up of the OptiTrain trial: exercise improve survival and recurrence in breast cancer
Helene Rundqvist • 14 Sep 2024
PREFERABLE-EFFECT: exercise improves fatigue, QoL, and inflammation in metastatic breast cancer
1:17
PREFERABLE-EFFECT: exercise improves fatigue, QoL, and inflammation in metastatic breast cancer
Helene Rundqvist • 14 Sep 2024

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals